Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Organ-on-a-Chip and 3D-Culture: Companies, Technologies and Approaches
Conferences  \  Organ-on-a-Chip World Congress & 3D-Culture 2017  \  Organ-on-a-Chip and 3D-Culture: Companies, Technologies and Approaches  \  Agenda  \  Marjorie Villien
RegisterLogin

Marjorie Villien's Biography


Marjorie Villien, Technology & Market Analyst - Microfluidic & Medical Technologies, Yole Développement

As a Technology & Market Analyst, Dr Marjorie Villien is member of the Microfluidic & Medical Technologies (MedTech) business unit at Yole Développement, the "More than Moore" market research and strategy consulting company. She is a daily contributor to the development of MedTech activities with a dedicated collection of market & technology reports as well as custom consulting projects. After spending two years at Harvard, Marjorie served as a research scientist at INSERM in the field of MRI & PET imaging. She has spoken at numerous international conferences and has authored or co-authored 11 papers and 1 patent. Marjorie Villien graduated from Grenoble INP and holds a PhD in physics & medical imaging.

Marjorie Villien Image

Currently Worth a Few Million Dollars, The Emerging Organs-on-Chips Market has the Potential to Become a Multi-Billion Dollar Market

Tuesday, 11 July 2017 at 10:30

Add to Calendar ▼2017-07-11 10:30:002017-07-11 11:30:00Europe/LondonCurrently Worth a Few Million Dollars, The Emerging Organs-on-Chips Market has the Potential to Become a Multi-Billion Dollar MarketSELECTBIOenquiries@selectbiosciences.com

Bringing a new drug to market is one of the longest and most costly paths any industry has to walk. The pharmaceutical industry therefore needs more predictive tools to make drug candidates fail earlier and cheaper. Other industries where toxicity testing is a major concern, such as cosmetics, agro-food and consumer goods, also need such solutions, in particular because animal testing is now banned for these industries in certain geographical areas. Several options have been envisioned, the most promising of which is certainly organs-on-chips. As a sign of confidence in this technology, significant funding has been allocated to organs-on-chips developers: DARPA and the NIH respectively awarded $140M and $76M over 5-year periods to support developments. In parallel, technology developers have raised more than $80M since 2012 with investors. But despite promises that make industrial players dream, we can barely speak about a real market today. Yole’s analysts estimate the combined sales of organs-on-chips devices and service offerings at no more than $7.5M in 2016. Indeed, very few players are already in the production and commercialization phase. Depending on the speed of adoption, and on the ability of organs-on-chips companies to overcome technical challenges and to upscale production, Yole’s analysts will detail different scenarios in which the market could grow at a compound annual growth rate from 2017-2022 of 38-57% to reach $60M-$117M in 2022. And this is only a first step. There is no doubt such technologies have the potential to become a multi-billion dollar market in the mid- to long-term future, given the billions of dollars they could help the industry to save every year.

Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonOrgan-on-a-Chip and 3D-Culture: Companies, Technologies and ApproachesSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors